Table 2.
Respiratory support at randomisation and proportion of deaths in each group
| No oxygen [n (%)] | On oxygen a [n (%)] | Invasive mechanical ventilation/ECMO [n (%)] | |
|---|---|---|---|
| Proportion of patients randomised based on respiratory support [4], [5], [6], [7] | |||
| RECOVERY–Dexamethasone (n = 6425) | 1535 (23.9) | 3883 (60.4) | 1007 (15.7) |
| RECOVERY–Hydroxychloroquine (n = 4716) | 1112 (23.5) | 2811 (59.6) | 793 (16.8) |
| RECOVERY–lopinavir/ritonavir (n = 4972) | 26 | 70 | 4 |
| ACTT-1 remdesivir (n = 1059) (missing data n = 42 from Table 2) | 127 (12.0) | 421+197 (58.3) | 272 (25.6) |
| Proportion of deaths in each group–randomisation based on respiratory support | |||
| RECOVERY–Dexamethasone (Fig. 3) Deaths (n = 1592) | 234 (14.7) | 980 (61.6) | 378 (23.7) |
| RECOVERY–Hydroxychloroquine (Fig. 3) deaths (n = 1206) | 156 (12.9) | 724 (60.0) | 326 (27.0) |
| ACTT-1 remdesivir (Table 2) Day 15 score data, deaths (n = 88) | 2 (2.3) | 50 (56.8) | 33 (37.5) |
ECMO, extracorporeal membrane oxygenation.
a
RECOVERY trials, oxygen-only respiratory support received at randomisation; ACTT-1 trial, patients both in Group 5 (supplemental oxygen) and Group 6 (non-invasive ventilation or use of high-flow oxygen).